CANCER - A new anti-cancer
strategy
Cancer is characterized by either the uncontrolled growth of
cells or the failure of cells to die normally. Often, cancer cells
spread (metastasize) to distant parts of the body, where they can
form new tumors. Treatment is often uncomfortable and intolerable.
BioMonde's response!
The Global
Burden of CancerThe World Cancer
Report tells us that cancer rates are set to increase at an alarming
rate globally, and could further increase by 50% to 15 million new
cases in the year 2020. In the year 2000, malignant tumors were
responsible for 12 per cent of the nearly 56 million deaths
worldwide from all causes. In many countries, more than a quarter of
deaths are attributable to cancer. In 2000, 5.3 million men and 4.7
million women developed a malignant tumor and altogether 6.2
million died from the disease.
Problems associated with Cancer treatments
- kills healthy cells;
bone marrow(makes blood cells);
hair follicles;
lining of the mouth;
digestive system;
- surgical complications;
- hemoglobin
- discomfort.
Common Cancer Treatments
-
Surgery
Radiation Therapy
Chemotherapy
Holistic Therapy
Cancer Cells Dividing

Dr. Jane Cooke Wright
Discovered Chemotherapy Treatment for Cancer

Development of a optimized, safe, effective and affordable class
of novel anti-cancer umbelliferone derivatives
(4-meythylumbellierone - 4MU), and anti-neoplasm derivatives.

- 4MU as a adjunct therapy in the management of metastatic, liver,
prostate, pancreatic, breast, brain, melanoma, and other
cancers.
- 4MU as a adminiculum to Gemcitabine and other anticancer chemotherapy treatments;
- 4MU as a anticancer chemotherapy prophylaxis;
- anti-neoplasm as a adjunct therapy to 4MU;
- anti-neoplasm as a adjunct therapy in the management of metastatic,
prostate, pancreatic, liver, breast, brain, melanoma, kaposi's
sarcoma and other cancers.
BioMonde is focused on preventing the progression of cancers and
to improving the tolerability and
effectiveness of chemotherapy drugs. According to cancer research,
hyaluronan synthase (HA) over expression is very much implicated in
malignant transformation and tumor progression, especially
metastasis cancers. By preventing the overexpression of HA it is
possible to slow or halt the progression of many Cancer's, and
significantly improve the effectiveness and tolerability of
anticancer drugs. Umbelliferone
derivatives (4-meythylumbellierone) are scientifically recognized as
potent HA over expression inhibitors, that help prevent tumor
metastasis based on its inhibitory effect on hyaluronan synthases as
a adminiculum in cancer chemotherapy.
Anti-neoplasm derivatives
administered in combination Umbelliferone derivatives
(4-meythylumbellierone) exert a potent synergy effect that greatly
improves the anti-cancer effects, especially metastasis cancer.
Anti-neoplasm derivations may also be administered independently of
Umbelliferone derivatives (4-meythylumbellierone).
Consequently, BioMonde's approach
to cancer healthcare means that patients now have access to a New
Anti-Cancer Oncology strategy, that improves the effectiveness and also lessens the discomfort associated
with existing anticancer chemotherapies.
REFERENCE MATERIAL
Published and Peer Reviewed Studies
click-here
View our product pipeline
click-here
Products containing umbelliferone derivatives
(4-Methylumbelliferone) click-here
HEPARVIT™ ProCELL
Products containing anti-neoplasm derivatives
click-here
ExCELL™
Hyaluronan

Medical research...........
Indicates that umbelliferone derivatives (4-meythylumbellierone)
administered as a preventive or management therapy for cancer, or
administered as a adjunct therapy to gemcitabine and other
anti-cancer drugs:
- Can reduce tumor metastasis to the liver by 30% or more;
- Targets pancreatic (KP1-NL) and other cancer cells and
decreases the cell surface HA, which prevents the cancer from
progressing;
- Targets pancreatic (KP1-NL) and other cancer cells and
decreases the cell surface HA, which exposes the cells to
anti-cancer drugs for destruction.
- Decreases the size of the primary and metastatic tumors more
than gemcitabine alone;
- Strongly suggests that a combination of gemcitabine and umbelliferone
derivatives (4-meythylumbellierone) and is effective
against human pancreatic and other cancer cells;
- Reduces elevated liver enzymes associated with chemotherapy
toxicity (drug induced Hepatitis);
- Improves red blood cell and platelet regeneration; tiredness, appetite, and digestive functions;
- Greatly improves effectiveness and tolerability when taken
as a prophylaxis before commencing anticancer treatment.
Indicates that the anti-neoplasm derivatives:
- Promote the generation of the bodies own cancer
killing cells;
- Help rebuild a damaged immune system.